home / stock / sabs / sabs news

SABS News and Press, SAB Biotherapeutics Inc.

Stock Information
Company Name: SAB Biotherapeutics Inc.
Stock Symbol: SABS
Market: NASDAQ
Website: sabbiotherapeutics.com
Menu
Get SABS Alerts

News, Short Squeeze, Breakout and More Instantly...
SABS - SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

MIAMI, March 19, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced the closing of an underwritt...
SABS - SAB Biotherapeutics slips 5%, prices $85M stock offering

2026-03-18 02:36:21 ET More on SAB Biotherapeutics SAB Biotherapeutics reports FY results Seeking Alpha’s Quant Rating on SAB Biotherapeutics Historical earnings data for SAB Biotherapeutics Financial information for SAB Biotherapeutics Read ...

SABS - SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

MIAMI, March 17, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced the pricing of an underwritten p...

SABS - SAB Biotherapeutics announces public stock offering; shares down

2026-03-17 16:13:58 ET More on SAB Biotherapeutics SAB Biotherapeutics reports FY results Seeking Alpha’s Quant Rating on SAB Biotherapeutics Historical earnings data for SAB Biotherapeutics Financial information for SAB Biotherapeutics Read ...
SABS - SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

MIAMI, March 17, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that it has commenced an underwri...

SABS - SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes

Results demonstrated early signals of C-peptide preservation T1D key opinion leader, Michael J. Haller, MD, provided a recorded webinar reviewing the SAB-142 Phase 1 data MIAMI, March 10, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceu...

SABS - SAB Biotherapeutics reports FY results

2026-03-09 17:22:20 ET More on SAB Biotherapeutics Seeking Alpha’s Quant Rating on SAB Biotherapeutics Historical earnings data for SAB Biotherapeutics Financial information for SAB Biotherapeutics Read the full article on Seeking Alpha For fur...
SABS - SAB BIO Reports Full Year 2025 Financial Results and Business Highlights

Advanced SAB -142 into registrational Phase 2b SAFEGUARD study with multiple patients dosed; enrollment ongoing and on track to complete enrollment by end of 2026 with topline data expected in 2H 2027 Reported Phase 1 clinical data, including healthy volunteer, redosing, and T1D cohorts suppo...

SABS - SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director

David Zaccardelli, Pharm.D. joins Board as Chair Rita Jain, M.D., joins Board as an Independent Director MIAMI, Jan. 07, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (h...

SABS - SABS Price Target Alert: $7.00. Issued by UBS

2026-01-07 02:05:28 ET Michael Yee from UBS issued a price target of $7.00 for SABS on 2026-01-07 06:01:00. The adjusted price target was set to $7.00. At the time of the announcement, SABS was trading at $3.62. The overall price target consensus is at $7.00 with high pr...
Next 10